Search academic texts

Information × Registration Number 0399U002815, 0199U003779 , R & D reports Title Сlinical trial of the drug"ERBISOL-2" PE "Laboratory Erbis" for the patients with chronic persisted hepatitis. popup.stage_title Клінічне випробування препарату "ЕРБІСОЛ-2" ПП "Лабораторія Ербіс" у хворих на хронічний персистуючий гепатит. Head Svintsits'kyj Anatolij Stanislavovych, Доктор медичних наук Registration Date 26-10-1999 Organization National medical university popup.description2 There is limited clinical research of the new ukranian hepatoprotectial endogenous regenerative biological immunomodulator - drug ERBISOL-2, which was created in PE "Laboratory Erbis", for treatment of сhronic diffuse diseases of liver. 15 patients of comparative group with analogic diagnosis had treatment with application of ERBISOL. 20 patients of control group with chronic persisted hepatitis had ordinary traditional treatment without use of drugs ERBISOL-2 and ERBISOL. It was found that hepatoprotectial effectiveness of drugs ERBISOL-2 and ERBISOL is equivalent. No complications and adverse effects of use ERBISOL-2 were observed. Product Description popup.authors popup.nrat_date 2020-04-03 Close